Deutsche Bank AG Increases DBV Technologies S.A. (DBVT) Price Target to $56.00

DBV Technologies S.A. (NASDAQ:DBVT) had its target price raised by Deutsche Bank AG from $46.00 to $56.00 in a report released on Sunday, October 8th.

Other equities research analysts have also recently issued reports about the stock. Zacks Investment Research upgraded shares of DBV Technologies from a hold rating to a buy rating and set a $50.00 price objective for the company in a research report on Tuesday, August 29th. BidaskClub upgraded shares of DBV Technologies from a hold rating to a buy rating in a research report on Tuesday, July 25th. HC Wainwright reiterated a buy rating and set a $50.00 price objective on shares of DBV Technologies in a research report on Thursday, July 6th. Jefferies Group LLC reiterated a buy rating on shares of DBV Technologies in a research report on Thursday, August 31st. Finally, Citigroup Inc. increased their target price on shares of DBV Technologies from $43.00 to $57.00 and gave the stock a buy rating in a research note on Monday, October 2nd. One analyst has rated the stock with a sell rating, one has issued a hold rating and nine have issued a buy rating to the stock. The stock has a consensus rating of Buy and an average price target of $56.29.

DBV Technologies (NASDAQ:DBVT) traded down 1.76% during trading on Friday, reaching $48.48. The company’s stock had a trading volume of 25,104 shares. The firm has a 50-day moving average price of $44.38 and a 200-day moving average price of $39.06. DBV Technologies has a 52 week low of $31.87 and a 52 week high of $50.57. The firm’s market capitalization is $2.23 billion.

TRADEMARK VIOLATION NOTICE: “Deutsche Bank AG Increases DBV Technologies S.A. (DBVT) Price Target to $56.00” was originally reported by BBNS and is the property of of BBNS. If you are viewing this report on another website, it was copied illegally and republished in violation of international trademark and copyright laws. The legal version of this report can be read at https://baseballnewssource.com/markets/dbv-technologies-s-a-dbvt-given-new-56-00-price-target-at-deutsche-bank-ag/1701815.html.

Institutional investors and hedge funds have recently bought and sold shares of the company. Dynamic Technology Lab Private Ltd purchased a new position in shares of DBV Technologies in the second quarter worth about $222,000. Victory Capital Management Inc. purchased a new position in shares of DBV Technologies in the first quarter worth about $303,000. Airain ltd purchased a new position in shares of DBV Technologies in the second quarter worth about $333,000. Sit Investment Associates Inc. purchased a new position in shares of DBV Technologies in the second quarter worth about $698,000. Finally, Jane Street Group LLC purchased a new position in shares of DBV Technologies in the first quarter worth about $853,000. Hedge funds and other institutional investors own 45.52% of the company’s stock.

DBV Technologies Company Profile

DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company’s therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin.

Analyst Recommendations for DBV Technologies (NASDAQ:DBVT)

Receive News & Ratings for DBV Technologies S.A. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV Technologies S.A. and related companies with our FREE daily email newsletter.

 


Latest News

Houston’s Dallas Keuchel Could Make Relief Appearance in Game 7
Houston’s Dallas Keuchel Could Make Relief Appearance in Game 7
Houston Astros Relying on Justin Verlander to Save Their Season
Houston Astros Relying on Justin Verlander to Save Their Season
Clayton Kershaw Gets Chance to Pitch LA into Fall Classic
Clayton Kershaw Gets Chance to Pitch LA into Fall Classic
Aaron Judge and Gary Sanchez Have Break Out Games
Aaron Judge and Gary Sanchez Have Break Out Games
Justin Turner Joining Postseason Legends
Justin Turner Joining Postseason Legends
PED Use Cost Alex Rodriguez Millions and His Reputation
PED Use Cost Alex Rodriguez Millions and His Reputation


Leave a Reply

 
© 2006-2017 BBNS.